Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
CCL5/CCR5 axis in human diseases and related treatments

Zhen Zeng, Tianxia Lan, Yuquan Wei, Xiawei Wei*

Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu, Sichuan 610041, PR China

Received 11 July 2021; received in revised form 8 August 2021; accepted 12 August 2021

Available online 26 August 2021

KEYWORDS
Cancer;
CCL5/CCR5;
Infection;
Therapy

Abstract
To defense harmful stimuli or maintain the immune homeostasis, the body produces and recruits a superfamily of cytokines such as interleukins, interferons, chemokines etc. Among them, chemokines act as crucial regulators in defense systems. CCL5/CCR5 combination is known for facilitating inflammatory responses, as well as inducing the adhesion and migration of different T cell subsets in immune responses. In addition, recent studies have shown that the interaction between CCL5 and CCR5 is involved in various pathological processes including inflammation, chronic diseases, cancers as well as the infection of COVID-19. This review focuses on how CCL5/CCR5 axis participates in the pathological processes of different diseases and their relevant signaling pathways for the regulation of the axis. Moreover, we highlighted the gene therapy and chemotherapy studies for treating CCR5-related diseases, including the ongoing clinical trials. The barriers and perspectives for future application and translational research were also summarized.

Introduction
Chemokine is a molecular family about 8–10 kD that attracts different cytokines, cells and substance to specific sites. These small proteins regulate the positioning of cells, and are involved in a wide spectrum of biological processes such as homeostasis, angiogenesis, metastasis, immune response, inflammation and chemotaxis.\textsuperscript{1–3} Based on the number of amino acids between the first two cysteine residues, chemokines are classified into four subfamilies, CXC, CC, CX3C and XC.\textsuperscript{4} CCL5, also called RANTES (Regulated upon Activation, Normal T Cell Expressed and
Presumably Secreted), belongs to CC subfamily of chemokines. Most inflammatory cells can express CCL5, among them, T cells and monocytes are the most common types of CCL5-expressing cells. While CCL5 can bind to CCR1, CCR3, CCR4 and CCR5, it has the highest affinity to CCR5.\(^5\)\(^-\)\(^7\) CCR5 (also known as CD195), a G-protein-coupled receptor (GPCR), whose transcription is regulated by CREB-1.\(^8\) It expresses on T cells, smooth muscle endothelial cells, epithelial cells, even parenchymal cells etc.\(^6\)\(^,\)\(^9\) Besides CCR5, CCR1 also combine to CCL3 (MIP-1\(\alpha\)), CCL4 (MIP-1\(\beta\)) with a N-terminal extracellular tail.\(^10\) Additionally, CCR5 is the most important receptor that allows HIV-1 infection with gp-120 combination, thus it has been considered as a promising target for anti-HIV therapies.\(^11\)

In different conditions, the function of CCL5/CCR5 axis varies, which might be concerned with HIV infection,\(^1\) cell proliferation,\(^13\) migration, angiogenesis,\(^14\) metastasis\(^15\) and survival.\(^1\)\(^,\)\(^16\) Nowadays, CCL5/CCR5 has been studied in many diseases such as inflammation, cancers,\(^3\) virus infections\(^7\) and immune responses.\(^15\) This review focuses on the downstream and upstream of CCL5/CCR5 and how they are related to the pathological processes of diseases. Furthermore, the strategies to treat cancers or to induce an anti-tumor microenvironment by targeting CCL5/CCR5 axis are discussed. Moreover, the current and classical therapies for CCR5-related diseases are highlighted and summarized.

**Downstream and upstream pathway of CCL5/CCR5 axis**

**Downstream pathway of CCL5/CCR5**

It has been reported that the downstream pathway of CCL5/CCR5 including PI3K/AKT, NF-\(\kappa\)B, HIF-\(\alpha\), RAS-ERK-MEK, JAK-STAT and TGF-\(\beta\)-smad pathways are associated with cell proliferation, angiogenesis, apoptosis, invasion, division, metastasis and inflammation.\(^5\)\(^,\)\(^17\)\(^-\)\(^20\)

CCL5/CCR5 axis could contribute to the activation of AKT and GSK-3b in PI3K/AKT pathway, thus regulating its downstream. Specifically, PI3K gets phosphorylated after CCL5 binding to CCR5, and contributes to the phosphorylation of the serine 473 of AKT. The AKT/PKB complex then phosphorylates GSK-3 to interrupt its activities. The expression of several downstream proteins is either activated or arrested (Fig. 1A).\(^20\) For example, the expression level of Bcl2 is upregulated to promote cell apoptosis.\(^21\) \(\beta\)-catenin gets phosphorylated and then degraded;\(^22\)\(^,\)\(^23\) the level of Cyclin D, a crucial protein for the regulation of cell cycle, can be arrested by inactivated GSK-3.\(^23\) In the PI3K/AKT/mTOR pathway, CCL5/CCR5 phosphorylates 4E-BP1, which pushes mTOR-4E-BP1/S6K1-eIF4F pathway forwards. As soon as mTOR, a tyrosine kinase, receiving signaling from CCL5/CCR5/PI3K/AKT, it phosphorylates 4E-BP1, S6K1 and eIF4F gradually. After that, activated eIF4F dissociates 5’-untranslated region (UTR) and promotes mRNA translation. Moreover, CCL5/CCR5-mediated PI3K/AKT phosphorylates Thr1462 of TSC-2, thereby prevent the formation of TSC-1/TSC-2 complex. This mediates the de-inhibition of Rheb, promoting the activation of mTOR and its downstream pathways (Fig. 1B). In reverse, mTOR can directly activate AKT pathway and send signals downstream.\(^24\)\(^,\)\(^25\) CCL5/CCR5 could also activate hypoxia inducible factor \(\alpha\) (HIF-\(\alpha\)) pathway by improving the stability and accumulation of HIF-\(\alpha\).\(^26\) At a hypoxia situation, HIF-\(\alpha\) initiates angiogenesis processes via a von Hippel Lindau protein (VHL) related ubiquitin degradation or HIF response element (HRE)\(^27\)\(^,\)\(^28\) (Fig. 2). CCL5/CCR5 phosphorylated p65 serine 536 can modulate signaling at both protein and mRNA levels through NK-xB pathway with a co-activator\(^29\) (Fig. 3). Up to date, it has been found that NF-xB pathway is associated with up-regulated expression level of Inhibitors of Apoptosis Proteins (IAPs), FLICE-like inhibitory proteins (FLIPs) and matrix metalloproteinase (MMP) proapoptotic protein as well as lower p53 level.\(^30\)\(^-\)\(^33\) CCL5/CCR5 can initiate RAS-ERK-MEK pathway by phosphorylating MEK and enhancing the kinase activity.\(^34\)\(^,\)\(^35\) For example, while downstream proteins like Msk1, RSK and Mnkt\(^36\)\(^,\)\(^37\) are secreted for contributing to chromatin remodeling or protein synthesis, Ets, ELK-1 and SAP-1 are able to modify transcription.\(^38\)\(^-\)\(^40\) In addition, the activation can activate PI3K/AKT pathway to act synergistically.\(^41\) JAKs at adjacent receptors approach each other and get trans-phosphorylation after CCL5/CCR5 combination. Src homology 2 domain (SH2) of STAT and SOCS (suppressor of...
cytokine signaling) family enable receptor binding, which promotes gene transcription.\textsuperscript{42,43} As evinced by the T cell lymphoma seen in clinical patients’ tissues, CCL5/CCR5 upregulate DNA methyltransferase 1 (DNMT1) expression level in malignant T cells.\textsuperscript{44} Additionally, tumor associate macrophage, especially M2 macrophage, release CCL5 to

**Figure 2** CCL5/CCR5 axis in HIF-\(\alpha\) pathway. At normoxia, HIF-\(\alpha\) could bind to PHD and undergo a VHL related ubiquitin degradation. When the oxygen level is low, HIF-\(\alpha\) would accumulate and complex with HIF to form HRE. Next, HRE would bind to the promoter of gene and amplify genes.

**Figure 3** CCL5/CCR5 axis in NF-\(\kappa\)B pathway. PI3K/AKT, phosphorylated \(p65\) serine 536 mediate cascade phosphorylation of IKK and IkB subunits, then NF-\(\kappa\)B gets activated. NF-\(\kappa\)B enters cell nucleus after the ubiquitin-related degradation of phosphorylated IkB.
Upstream regulators of CCL5/CCR5

Numerous studies have revealed the upstream regulators modulating CCL5/CCR5 signaling, including plasminogen activator inhibitor-1 (PAI-1), kruppell-like zinc-finger transcription factor 5 (KL5F), SOCS-1, Rig1 etc. For instance, PAI-1 could activate the secretion of CCL5, which in turn contributes to PAI-1 production, forming a positive feedback loop. Resultantly, PAI-1 as a regulator of CCL5 could promote cell migration, angiogenesis and inhibit cell apoptosis through MMPs and cytokines secretion at a preferable concentration. In addition, activated c-Jun N-terminal kinase could bind to the promoter of CCL5 gene and regulate the initiation of the transcription. Studies have shown that there is a positive correlation between the level of enhancer of zeste homolog 2 (EZH2) and CCL5. EZH2 regulates epigenetic gene through regulating the methylation of histone H3 lysine 27 (H3K27). Moreover, HER2 and phosphatase and tensin homolog deleted on chromosome ten (PTEN) are a pair of cancer-related proteins that are closely associated with metastasis. The increased level of HER2 and the decreased level of PTEN will result in more CCL5, IL-6 and IL-8 secretion.

External stimuli could also regulate CCL5/CCR5 signaling. Vascular damage-resulted angiotensin 2 (Ang2) upregulation would lead to the enhanced transcription level of CCL5 mRNA in perivascular adopt tissue (pVAT). As a consequence, the CCR5+ leucocytes would migrate to pVAT and IFN-γ secretion also prolongs immune response. When it comes to irradiation, the transcription of CCL5 can be initiated by cGAMP-STING signaling pathway as interferon-stimulated genes (ISG). Alternatively, oncogenic events like Neu-T, H-RAS or c-SRC stimulation also activates CCL5/CCR5 signaling, which may lead to the enhancement of tumor cell aggressiveness.

Besides of activators of CCL5, researchers have also already found some inhibitors. It has been demonstrated that SOCS-1, Rig1 and abnormal LDH could downregulate the expression of CCL5. However, the underlying mechanism has not been fully uncovered so far.

CCL5/CCR5 and diseases

As reported by previous studies, the abnormal interaction of CCL5/CCR5 has been found in multiple types of inflammation, including hepatitis, atherosclerosis, and microglia inflammation. Some viral infections are also mediated by CCL5/CCR5 axis. More importantly, the elevated level of CCL5/CCR5 have been found in different types of cancers including gastric cancer, breast cancer, lung cancer, osteosarcoma, prostate cancer and pancreas cancer. Additionally, in several other diseases, such as diabetes, Alzheimer’s disease and endometriosis, CCL5/CCR5 was also found to be expressed in an aberrant manner.

Inflammations and infections

When getting damaged, pro-inflammatory factors are released into damaged tissues. Common pro-inflammatory factors are tumor necrosis factor (TNF), interleukin (IL) and TGF-β.

Oral lichen planus
First example is oral lichen planus (OLP), which is characterized by the liquefaction degeneration of basal epithelial cells. The lesion is caused by the over proliferation and activation of T cells. Basically, CCL5/CCR5 axis attracts T cells, allowing their proliferation and activation. Once T cells interact with epithelium, CCL5/CCR5 axis would cause the basal keratinocyte damage and initiate inflammation. In addition, Th1 cells secret IFN-γ to increase CCL5 expression and aggravate epithelium damage. On the other hand, OLP-related mast cell degranulation could cause upregulation of the cytokines mediating the expression of CCL5, such as TNF-α. As a result, the increased CCL5 would strengthen the accumulation of specific T cells, which further prolongs the inflammatory response.

Atherosclerosis

Previously, atherosclerosis is viewed as a lipid-initiated disease, a gene mutation disease or a receptor deletion disease. But as the scientists delve deeper into the pathology of the disease, it is now widely accepted that atherosclerosis is an inflammatory disease. Moreover, following the development of atherosclerosis, cytokines’ level would be upregulated in both peripheral blood and local tissues. MMP9 secreted from macrophages increases and helps with the generation of plaques. Besides, there are many co-action factors, such as perforin-1, vascular cell adhesion molecule-1 (VCAM-1), IL-6, selectin, TNF-α, etc., being involved in the whole pathologic process. Further, it has been reported that CCL5/CCR5 could attract T cells to release these inflammatory factors and worsen the inflammatory damage. Also, by acting with vascular smooth muscle cells (SMCs), the cell-mediated immune response would be prolonged. As a factor affecting vascular function, SMCs’ behaviors are critical for the metabolism of vascular cells. It has been shown that the CCL5/CCR5 interaction could influence the proliferation rate and migration of SMCs via PI3K/AKT, NF-κB, Ras/MEK pathways. Meanwhile, overexpression of CCL5 mediated by Ang2 gives rise to unstable lipid plaque and leads to vascular neointimal thickening, which may cause atherosclerosis. Incidentally, CCL5-related atherosclerosis is associated with hypertension and the development of obesity, which are two common risk factors for cardiovascular diseases. Interestingly, people with CCR5△32 mutation have low risk of getting cardiovascular diseases such as coronary disease and myocardial ischemia, as the mutation downregulates the level of factors that increase the risk of getting cardiovascular diseases (low density lipoprotein and
triglycerides), while upregulate the level of factors that decrease the chance to prevent them (high density lipoprotein, cholesterol).77

Inflammatory bowel diseases
It has been reported that inflammatory bowel diseases (IBDs), a chronic inflammation, may be related with CCL5/CCR5 axis. The CCL5 level was found to be elevated in the damaged tissue and then induced the influx of inflammatory factors. Moreover, CCR5−/− mice-IBD model has also shown that CCR5 antagonists are effective in the treatment of IBDs.78 Besides, rheumatic disease (RA) is an autoimmune disease caused by the infiltration of Th1 cells. In RA patients, CCR5+ T cells, monocytes, and NK cells significantly thrive and accumulate in the synovial effusions as compared with those in the peripheral blood. Meanwhile, various types of chemokines, including high level of CCL5, were also detected in synovial fluid and synovial tissue of RA. This evident example may prove the important role of CCL5/CCR5 axis-mediated inflammatory responses in the development of RA.

Hepatic inflammation
Drug-related hepatic inflammation is partially caused by pro-inflammatory factors. Normally, continuous activation of N-acetyl-p-benzoquinone (NAPQI)-related liver macrophages (Kupffer cells [KC]) results in the secretion of cytokines, neutrophil homing and the migration of macrophages. These cellular and molecular processes could facilitate hepatic inflammation.79,80 New studies have shown that, CCL5/CCR5 interaction can accelerate hepatic inflammation process via NF-κB pathway.81–83 Notably, both M1 and M2 macrophages participate in this process. M1 phenotype, with the pro-inflammation roles, aggravates inflammation by secreting pro-inflammatory factors IL-1α and prompting the infiltration of CD11b+ Gr-1+ cells. In contrast, M2 phenotype removes the necrotic cell debris to alleviate the inflammation. After cascade phosphorylation of IKK and IkB subunits, NF-κB pushes the polarization balance towards TAM-M1 rather than TAM-M2, accelerating the progression of inflammation.84

COVID-19
Additionally, CCL5/CCR5 axis also participates in virus infections. The unprecedented pandemic disease, COVID-19, is caused by the infection of SARS-CoV-2. Since the outbreak of COVID-19, substantial efforts have been made to find the effective treatment of it. It has been shown that inhibition of CCL5/CCR5 axis by monoclonal antibody, leronlimab, can relieve the symptoms of patients who are critically ill.85 Also, it has been observed that, following the anti-CCR5 treatment, the level of inflammatory molecules such as CCL5, IL-6, TNFα were reduced.86 Furthermore, 17 years ago, patients with SARS also had shown elevated CCL5 level.87

Other infections
Besides, Toxoplasma gondii and Staphylococcus aureus are able to kill cells without triggering host immune response by taking advantage of CCL5/CCR5 axis.88 Conversely, CCR5 in West Nile virus (WNV) infection plays an antiviral role. The chemotaxis of CCL5/CCR5 could initiate CD4+/CD8+ T cell-mediated immunity, NK cell migration and the infiltration of macrophages into infected tissues.89

Cancers
Recently, CCL5/CCR5 axis has been extensively studied in the context of tumorigenesis of different types of cancers including chondrosarcoma, gastric cancer, breast cancer, pancreatic cancer, head and neck cancer, etc.5 Among them, CCL5/CCR5 axis always intends to create more suitable microenvironment for tumor cell survival. One the one hand, CCL5/CCR5 triggers cell signaling like PI3K/AKT, NF-κB, ERK/MEK and HIF-α to give tumor cell character of uncontrolled proliferation and immortality. Another the other hand, these signaling pathways regulate MMPs, growth factors and inflammatory factors to remove barriers for tumor metastasis and invasion.90 Moreover, CCL5/CCR5 also recruits Tregs, MDSCs and TAM to induce immunosuppression of the tumor.9

Chondrosarcoma
Chondrosarcoma is a kind of malignant bone tumor due to the chondrocyte or mesenchymal leaf tissue lesions. The invasion and migration of chondrosarcoma are closely related to CCL5/CCR5 axis, with PI3K/AKT, ERK and NK-κB pathways taking part in MMP upregulation. Researchers have shown that the expression level of CCL5 was elevated in cancerous cartilage. Although the levels of various MMPs proteins were increased in human chondrosarcoma cells, only the level of MMP3 were increased along with the elevation of CCL5 level. And it can be reduced by CCR5 inhibitor (Met-CCL5) CCR5 or co-culturing with siRNA.91–93 A study in Israel has demonstrated that CCR5 engagement by CCL5 could induce the phosphorylation of tyrosine residues on ERK and initiate ERK-MEK signaling pathway, which causes the adhesion of T cells.94 Besides, more studies have proved that CCL5/CCR5-mediated cell invasion and migration are dependent on degradation of extracellular matrix (ECM) by MMP3 via PI3K/AKT, ERK and NK-κB pathways. CCL5/CCR5 axis phosphorylates Akt Ser473 and GSK-3β, which are directly or indirectly involved in the regulation the process. Then, the level of MMP3 increases in a time-dependent manner to achieve cell migration. However, opinions on NF-κB-mediated MMP3 expression are controversial. Some hold the view that p65 Ser536 gets phosphorylated by CCL5/CCR5 through PI3K/AKT pathway. Moreover, the activated NF-κB pathway could assist the transcription of MMP3, which is indispensable for expanding the cell invasion depth and the migration range. However, some others hold the opposite views. Borghaei RC et al have found that NF-κB could suppress the expression of MMP3 via a polymorphic site-stromelysin IL-1 responsive element (SIRE) site binding.95 According to the report, the expression of MMP3 could be suppressed by the binding of NF-κB and the polymorphic site in promoter.96

Osteosarcoma
Osteosarcoma is a malignant childhood-bone tumor. Most of the patients with this disease are children. Derived from mesenchymal stromal cells (MSC), osteosarcoma grows rapidly, which requires fast angiogenesis and active cell
CCL5/CCR5 axis in human diseases and related treatments

migration. This is for the most part due to the CCL5/CCR5 axis-mediated adhesion production and VEGF secretion in tumor microenvironment (TME). In patients with osteosarcoma, CCL5/CCR5 axis is commonly found to be activated at pathological tissues and tumor microenvironment. Along with elevated expression level of CCL5 in osteosarcoma tumor microenvironment, PKC\(\alpha\) and c-Src are highly activated, leading to the upregulation of HIF-\(\alpha\) miRNA level.\(^{26}\) Moreover, VEGF is the main functional downstream of PKC\(\alpha\)-c-Src- HIF-\(\alpha\) pathway. CCL5/CCR5 axis promotes VEGF production by attracting endothelial progenitor cells (EPCs). The CCL5-overexpressing-osteosarcoma makes EPCs migrate to abnormal sites. Then, the secreted VEGFs accelerate the process of angiogenesis.\(^{98,99}\) As for the migration of tumor cells, NK-\(\kappa\)B pathway increases the yields of many adhesion molecules such as \(\alpha\)v\(\beta\)3 integrin, E-selectin etc. at tumor cell surface, which can bind to proteins on ECM. Among them, \(\alpha\)v\(\beta\)3 integrin is one of the major drivers. Previous studies indicated that CCL5/CCR5 axis is responsible for the activation of MEK, which may participate in NK-\(\kappa\)B p65 Ser536 phosphorylation process. It has been shown that the activity of CCL5-mediated NF-\(\kappa\)B promoter could be reduced by antibodies against CCR5 as well as the inhibitors of Met-RANTES or MEK (PD98059, and U0126). Thus, mediated by NK-\(\kappa\)B pathway, the secretion of \(\alpha\)v\(\beta\)3 integrin by tumor cells contributes to the migration of osteosarcoma cells. Similarly, in lung cancer, not only NF-\(\kappa\)B, but also PI3K/AKT can up-regulates \(\alpha\)v\(\beta\)3 integrin expression at tumor cell surface, which contributes to the migration. In addition, EZH2 enhances CCR5 expression in lung cancer to strengthen tumor cell migration by migration. In addition, EZH2 enhances CCR5 expression in lung cancer, not only NF-

**Hodgkin lymphoma**

Classical Hodgkin lymphoma (cHL) is a unique hematopoietic neoplasm. The character of cHL is Hodgkin and Reed-Sternberg cells (H-RS cells) infiltration of blood.\(^ {101}\) The tumor immunosuppression realized main contributes to chemotactic function of CCL5/CCR5 to mesenchymal stromal cells (MSC). Recent researches demonstrated CCL5/CCR5 signaling is involved in cHL tumor growth and TME formation. There, CCL5 and CCR5 express widely at surface of cHL tumor cells, monocytes, lymphocytes and stromal cells. Within the cHL TME, H-RS cells can secret CCL5 to attract inflammatory cells inside and cause FGF2, TGF\(\beta\) and TNF\(\alpha\) explosion. For instance, MSC migration and monocytes recruitment.\(^ {102}\) Then MSCs further select CCL5 to chemotaxis more CCR5\(^{+}\) macrophages to the lesions. By this, cHL gets growth even reprogram large macrophages to achieve immunosuppression.\(^ {103}\)

**Melanoma**

As melanoma is used to be seen as neural-crest derived melanocytes, fewer scientists connect it with EMT. However, newly reports pointed that EMT do exist in melanoma process, even is a major determinant of its metastasis.\(^ {104,105}\) Liu et al demonstrated CCL5-stimulated CCR5\(^{+}\) tumor cells are more metastatic. There, CCL5/CCR5 recruits Tregs with high TGF\(\beta\)1 expression. Differently, TGF\(\beta\)1-induced EMT here is found to activated PI3K/AKT/GSK-3 pathway, not smad. Following E-cadherin down-regulation and N-cadherin, vimentin, snail and slug upregulation, cancerous melanocytes undergo EMT-like process and metastasis.\(^ {106}\) In addition, CCL5 production triggered by lymphocytes in melanoma bind to CCR5, following with release of cytochrome c from mitochondria. The process joins in caspase-9/3 activation that leads to apoptosis of tumor infiltrating lymphocytes.\(^ {107}\)

**Head and neck cancer**

Salivary adenoid cystic carcinoma (SACC) and oral squamous cell carcinoma (SCC) are two types of head and neck cancer known so far, which are closely related to CCL5/CCR5 axis. However, their tumor characters and pathogenic mechanism behind are totally differenced. Perineural invasion (PNI) is induced to occur more often at SACC by CCL5/CCR5 axis activation, while, the axis-mediated MMP9 production enhanced by leukocyte is the key factors in SCC patients for tumor invasion and migration.

SACC is a subtype of salivary gland carcinoma. As the hallmark of SACC, PNI is linked with tumor progression and poor prognosis.\(^ {107}\) It has been reported that the activation of CCL5/CCR5 axis is involved in the progression of SACC through participating in the process of PNI. Notably, CCL5 generated from dorsal root ganglia (DRG) could lead to the growth of longer neurite and more branches in DRG. When CCL5 binds to the CCR5 on the surface of SACC cells, the cells would chemotactically migrate towards DRG and induce PNI. Thus, the CCL5/CCR5 axis-mediated PNI is important for the development of SACC.\(^ {108}\)

SCC is a malignant carcinoma with high rate of metastasis and invasiveness. Addictions to cigarettes and alcohol are two risk factors of SCC due to chronic epithelial irritation.\(^ {109}\) Among several cell lines, CCR5\(^{+}\)CCL5\(^{+}\) high expression SCC4 cell line shows higher mobility and aggressiveness. Researches demonstrated the signaling behind it depends on CCL5/CCR5 axis initiated MMP9 overexpression. CCL5 in TME stimulates CCR5\(^{+}\) tumor cells, causing PLC\(\beta\)3 phosphorylation. Then PKC\(\alpha\) gets activated, involvement of PI-PLC pathway, and enhances NF-\(\kappa\)B activity to bind MMP9 promoter. Thus, MMP9 expression and enzyme activity get increased by CCL5/CCR5-, PLC\(\beta\)3-, PKC\(\alpha\)-, NF-\(\kappa\)B-dependent pathway.\(^ {110}\)

**Esophageal cancer**

Esophageal cancer, another digestive tract tumor, has been recently proved related to CCL5/CCR5 axis. Researchers cultivated 4 ESCC cell lines and found CCL5 overexpression, especially in TWES-4LN cell line. Furthermore, CCL5 secreted by cells derived from lymph nodes bind to CCR5\(^{+}\) TAM, CCR5\(^{+}\) MDSC and CCR5\(^{+}\) Treg to recruit them to tumor lesion. Thus increase the growth rate, migration and invasive ability of tumor cells.\(^ {111}\)

**Gastric cancer**

As a type of malignant tumors with high prevalence, the early diagnose of gastric cancer is of most importance. In the process of oncogenesis, the gastric mucosa epithelial cells undergo uncontrolled proliferation, migration etc. Worthy, CCL5/CCR5 axis focus on influencing the cell cycle of tumor cells through abnormally activating NF-\(\kappa\)B, mTOR and PI3K/AKT signaling pathways. At the molecular level, the cell
division-related genes like cyclin D1, c-Myc and Dad-1 are overexpressed at tumor cell surface. They cooperate with each other to strengthen the mitogenesis. Furthermore, mTOR-mediated glycolysis and ATP production provide sufficient energy for the growth of tumor cells. In this process, CCL5/CCR5 combination triggers mTOR signaling continuously for cell proliferation.112,113 Also, CCL5/CCR5-mediated DNMT1 over-expression could methylate promoter of gelsolin (GSN) and thereby hamper the expression of GSN. In this way, F-actin becomes abnormal and contributes to tumor survival.114 Additionally, mTOR-4E-BP1/S6K1-eIF4F pathway activated by CCL5/CCR5 complex takes the role to disassociate 5'-untranslated region (UTR) and promote tumor survival-related mRNA translation. GSN suppression and eIF4F activation are all favorable for the progression of gastric cancer.45 H. pylori is a potential cause of gastric cancer. Once infected, chemokines, growth factors and cytokines including CCL5, IL-10, MMPs, VEGF etc. would be secreted. Apart from that, cell chemotactic function of CCL5/CCR5 also play a pivotal role. Stimulated by these cytokines, peripheral blood monocytes are transformed into TAMs and MDSCs, which are recruited to inflammatory sites. Especially, elevated CCL5 level promotes the process of transformation. In addition, the pro-tumor role of TAM is gradually disclosed. Particularly, TAM could influence nearly all tumorigenesis processes, including but not limited to cell proliferation, metabolism, tissue remodeling, immunosuppression, tumor invasion, metastasis and EMT processes.115–117 TAM could release a variety of growth factors, including CCL5, into the tumor microenvironment. The mutual effects between cytokines and TAMs accelerates tumorigenesis. Meanwhile, TAMs could attract Tregs with some other chemokines like CCL22. In addition to TAM, CCR5+ myeloid-derived suppressor cells (MDSCs) and CCR5+ Treg can also be recruited by CCL5 and initiate immune response by enhancing IL-6 and IL-10.119,120 These cytokines suppress the immune response mediated by effector T cells and achieve tumor cell immunosuppression.121,122 By the way, MDSCs are also characterized with powerful immunosuppress function, resist not only the innate, but also the acquired immune cells functions.123,124 Additionally, mediated by KLF5, CAF generated in tumor sites makes it easy for the effective metastasis. Newest studies have demonstrated that CCL5/CCR5 axis could support the uncontrollable proliferation of tumor cells by affecting their metabolism activities.125

Colorectal carcinoma

In colorectal carcinoma, CD3+ T cell secret CCL5 to recruit macrophage, undergoing EMT and tumor growth. Also, CCL5/CCR5 induced phenotype switch from TAM-M1 to TAM-M2 can be used by tumor cells for further growth.126 In addition, higher expression of CCR5 at tumor cell surface is positive related to tumor metastasis. In colorectal carcinoma, CCL5/CCR5 axis influences cell cycle by upregulating mTOR or downregulation P53, P21, FOXM1 and EZF1. Thus, cyclin D1 and cyclin E1 are in moderate higher activity to activate CDK4/6/2 and promote G1/S phase of cell cycle.127,128

Breast cancer

Nowadays, breast cancer is one of the deadliest cancers.129 CCL5 is closely associated with the tumorigenesis of breast cancer. So as other tumor process, the binding of CCL5 and its receptor could initiate PI3K/AKT/mTOR pathway and enhance the proliferation, progression, transformation and resistance to apoptosis in breast cancer progression.130,131 In the past 10 years, it had been found that insulin-like growth factor 1 (IGF-1) pathway is involved in CCL5 upregulation of breast cancer cells. This process coordinates with αvβ3 integrin, collagen and other extracellular matrix proteins secretion, promoting invasion of tumor cells.132

In tumor microenvironment, the elevated level of CCL5 leads to high GLUT1 expression on the surface of cells. Under anoxic conditions of tumor microenvironment, glucose can only undergo anaerobic glycolysis. Thus, CCL5-mediated upregulation of GLUT1 provides enough energy for the proliferation of tumor cells as well as angiogenesis. Specifically, the upregulation of GLUT-1 and increment of glucose concentration is dependent on mTOR/AKT pathway. CCL5-mediated 4E-BP1 and GSK-3 phosphorylation initiate mTOR/AKT pathway, which allows the transcription of GLUT-1 gene.133,134 Moreover, the metabolic intermediates of glucose-anaerobic glycolysis, such as glucose-6-phosphate, pyruvate, peptide and lipid, are all enriched. These intermediates could undergo further catabolism through tricarboxylic acid (TCA) cycle and enzymatic hydrolysis, and then provide more energy. In breast cancer, researchers have also found that high concentration of IL-6 could stimulates various pathways, even increase the yield of CCL5. As mentioned, HER2-Pten balance adjustment contributes to this and accelerates breast cancer process. By contrast, Santos Mañes made a point that CCR5 expression could inhibit the progression of breast cancer through activated p53-mediated antitumor response.135 However, the idea that CCR5 promotes the tumorigenesis is still the current mainstream.

Pancreatic cancer

Different from other organs, the pancreas is hidden between the stomach and the posterior abdominal wall, which means it is difficult to visualize pancreatic lesions by image technologies such as X-ray, CT, MRI, etc. Actin polymerization was reported as a crucial factor in pancreatic cancer migration, which can be largely influenced by CCL5/CCR5 axis through RAS-ERK-MEK, RAS-Ral-Cdc42 and PI3K-AKT pathways activation. A pilot study has demonstrated that FOXP3 protein is overexpressed in human pancreatic ductal adenocarcinoma, which is correlative to patient’s poor prognosis. It has been proved that the motif-4 in the CCL5 promoter could bind to FOXP3 to directly initiate the transcription of CCL5. PDAC cells could recruit foxp3+ Tregs to boost the proliferation and metastasis of tumor cells.136,137

Another report shows that the protein and mRNA level of CCL5 rise up significantly in MACs/PCCs co-cultured samples. The CCL5 transactivated by IGF-1 pathway could initiate downstream signaling cascades and effector molecules via CCL5/CCR5 axis.138 Cell migration relies on actin polymerization. Scientists showed that CCL5/CCR5 axis could induce F-actin polymerization in pancreatic cancer. This process requires the participation of RAS-ERK-MEK, RAS-Ral-Cdc42 and PI3K-AKT pathways. RAS activates Cdc42 and PL3K and then stimulate the downstream second messengers for the gradient signal amplification. With the
assists of Arp2/3 complex and WASP/WAVE protein family, pseudopodia are formed and got polymerized, which confer the ability to migrate on cells.\(^{139}\)

**Prostate cancer**

Prostate cancer is one of the most common causes that leads death in males worldwide.\(^{129}\) Previous researches have already proved, during prostate cancer process, there is a high level of both CCR5 and CCL5 expression within intracellular pools.\(^{140}\) The CCL5/CCR5 combination in TME of prostate cancer promote cell proliferation by enhancing cyclin D1, c-myc in mTOR dependent pathway.\(^{141}\) Also, the axis can increase glucose uptake and ATP production for cell proliferation.\(^{142}\) Otherwise, CCL5/CCR5-induced NF-kB/STAT dependent angiogenesis is involved in.\(^{143}\) Apart from that, autophagy becomes another potential reason in prostate cancer process. As demonstrated before, androgen receptor (AR) downregulation by IL-6 directly results in TGF-\(\beta\)-induced MMP-9 overexpression and cell autophagy.\(^{90}\) Recently, scientists showed CCL5/CCR5 axis also inhibits AR signaling. It can decrease AR expression and transcriptional activity through HIF2\(\alpha\) signaling pathway. Then paxillin degradation and focal adhesion damage, allowing autophagy and cell migration.\(^{144}\)

**Other diseases**

Besides, some other chronic diseases such as endometriosis and type 2 diabetes (T2D), are related to CCL5/CCR5 axis. Endometriosis, a benign disease of women, which cause progressively worsen dysmenorrhea, infertility, as well as abnormal menstrual. Many potential factors are associated with the disease, including hormone imbalance, genetic abnormalities etc.\(^{145-147}\) Recently, it has been reported that the recruitment of CCR5\(^{+}\) MDSCs (especially Mo-CCR5\(^{+}\) MDSCs) could promote the development of endometriosis. Samples from the clinical study have demonstrated that the level of CCL5 was elevated in cell plasma and peritoneal fluid of late endometriosis patients. It has been observed that CCR5\(^{+}\) MDSCs could migrate to the endometriosis lesions\(^{148}\) and contribute to the progression of endometriosis through enhancing the generation of arginase (ARG-1), indoleamine2,3-dioxygenase1 (IDO), inducible nitric oxide synthase (iNOS) and PD-L1.\(^{149,150}\) The production of ARG-1 might be associated with the consumption of the amino acids that is required for the T cell function, thus, inhibiting T cells in several ways. In addition to that, both IDO and PD-L1 could act as suppressors for T cells.\(^{151,152}\) By the way, researches had showed CCL5/CCR5 axis-induced Treg recruitment leads a Fas-FasL-mediated T cell apoptosis with a decrease of T cell reactivity in endometriosis.\(^{46,153}\) In this way, CCL5/CCR5 axis promotes endometriosis progression through recruiting MDSCs into endometriosis lesions and T cell suppression.\(^{154}\)

In addition, CCL5/CCR5 axis also has protective functions. T2D is characterized by the insulin resistance due to IRS-1 S302 phosphorylation-mediated disassociation from insulin receptors.\(^{153}\) CCL5/CCR5 makes its way to inactivate AMPK\(\alpha\) via dephosphorylation pathway. Next, the inactivated AMPK\(\alpha\) fails to stimulate p70S6K, then leads to the suppression of IRS-1 S302 phosphorylation, which consequently erase the insulin resistance.\(^{156}\) Furthermore, CCL5/CCR5 axis could promote the translocation of GLUT4, the glucose channel, on T cell membrane, which increases the uptake of glucose.\(^{157}\)

**Treatment targeting CCL5/CCR5**

Above researches demonstrate how CCL5/CCR5 axis is important in tumorigenesis, migration, metastasis and prognosis.\(^{100,106,112,158}\) In addition, CCR5 secreted by tumor microenvironment is highly sensitive to drug blocking, especially in breast cancer.\(^{159}\) Therefore, the exploration of target therapies to block CCL5/CCR5 axis has broad application prospect in tumor therapy in the future. Nowadays, the development of small molecule inhibitors are the main strategies. Notably, inhibitors such as maraviroc, cencriviroc, anibamine, MET-CCL5, etc. have been evaluated clinically with anti-inflammatory and anti-cancer effects.

**Maraviroc**

Some known CCR5 inhibitors are able to slow the progression of CCR5 aberrant expression diseases down. Maraviroc, the first FAD-approved drug for treating HIV-infection, is also being used in some anti-tumor regimens. Directly, maraviroc competes with CCL5 to combine with CCR5, blocking the internalization of CCR5 and inhibiting T-cell chemotaxis.\(^{160}\) Acting as an antagonist of CCR5, maraviroc could inhibit the recruitment of mesenchymal-stromal cells (MSCs), monocytes and some growth factors by tumor cells, which could reduce the progression of cancer.\(^{126,161}\) Studies have shown that maraviroc could effectively prevent the further infiltration of classic Hodgkin lymphoma (cHL) by reducing heterospheroid self-assembling by cHL, HL-MSCs and monocytes;\(^{162}\) in breast cancer, it is able to control tumor cells metastasis, especially in lungs.\(^{162}\) At the same time, the migration of Treg could also be restricted by maraviroc; it also inhibits the accumulation of fibroblasts mediated by colorectal cancer.\(^{163}\) Indirectly, maraviroc possess the function of enhancing the efficacy of chemotherapy drugs. For example, maraviroc strengthen the anti-tumor effects of doxorubicin and bentuximab vedotin \textit{in vitro} model.\(^{103}\) Recently, it has been reported that maraviroc could be used in the treatment of diseases including hepatic steatosis of non-alcoholic fatty liver disease (NAFLD),\(^{164}\) cancers,\(^{159}\) graft-versus-host disease,\(^{165,166}\) heart diseases,\(^{167}\) lung diseases, type 1 diabetes,\(^{168,169}\) rheumatoid arthritis\(^{170}\) and hemorrhage.\(^{108}\)

Clinical trials considering maraviroc intervention are in full swing. Scientists are trying to combine this drug with conventional medical treatments and see if these therapies would be more effective (NCT01736813, NCT01276236, NCT02741323). Directed by Professor Niels, the clinical trial (NCT01736813) related to human colorectal cancer liver metastasis demonstrates how maraviroc protect metastasis by inhibiting CCL5/CCR5 axis. After analyzing 12 participants’ samples, scientists found the blockade of CCR5 by maraviroc can influence AKT and ERK pathways to lower down PIA53, VEGF, MIF etc. Also, CCL5/CCR5 axis is arrested and results in macrophage repolarization through STAT3.
pathway activation. The phase clinical trial proved the possibility of maraviroc treatment for colorectal cancer especially patients have tumor metastasis.126

Cenicriviroc

Cenicriviroc is an oral antagonist of dual chemokine receptor CCR2/CCR5, which inhibits the migration of monocytes. In comparison to maraviroc, cenicriviroc possesses higher efficiency in disruption of links between cells.171 Nowadays, cenicriviroc-related clinical trials have demonstrated that the drug has both antiviral and anti-fibrosis effects in the condition of infections, non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) (NCT02653625) and many other conditions.172,173

In NASH clinical trial (NCT02217475), patients are divided into three groups randomly, providing CVC, placebo or cross. After two-year cohort survey, Eric Lefebvre et al demonstrated patients with fibrosis response at the beginning maintained it one year later when treating with CVC. Contrarily, natural fluctuations of the disease in placebo group failed to reach such a great effect. Longer and larger clinical benefit may appear if prolong the study. However, side effects also increase like diarrhea, abdominal pain etc.174

Based on the CCL5/CCR5 axis’s function on macrophage migration and infiltration, J.P. Nicandro et al initiate an exploratory of CVC on PSC (NCT02653625). As a powerful anti-inflammatory and anti-fibrosis drugs, CVC blokes CCR5 positive leucocyte recruitment and relieve inflammation. Study showed an apparent median ALP absolute reduction at week 24 after treatment, which means less liver damage. Although key secondary efficacy endpoint was not achieved, the encourage data offer a new idea for targeting PSC.175

Anibamine

Anibamine is the first natural CCR5 antagonism. Similarly, after blocking CCR5/CCL5 interactions, Ca\(^{2+}\) flux gets limited and most prostate cancer cell lines decreased the proliferation rate. Meanwhile, abanimine could significantly change the morphology, metastatic and adhesion ability of M12 cancer cells. Additionally, its special side chain of high affinity to CCR5 makes it a favorable thera-

MET-CCL5 and others

Different from agents discussed above, MET-CCL5 is composed of amino end of CCL5 and a methionine. MET-CCL5 could prevent binding of CCL5 and CCR5. The special agent is usually used for reducing inflammatory response of peripheraly injured neve at late phase. Hyperesthesia can also be partially eased by MET-CCL5. These therapeutic effects are achieved by the reduction of macrophages infiltration and pro-inflammatory cytokine mediated by MET-CCL5-interference.178 Clinical trials on the drug are still absent. Vicriviroc, another CCR5 antagonist, whose role is preventing tumor cells migrate to targeted organs.159 It limits Ca\(^{2+}\) signaling and powerful antiretroviral activity in a phase II trial (NCT00523211). Disappointingly, it failed to further demonstrate its efficacy in another phase III trial (NCT00474370).

Besides, some non-classical agents like TAK779, zole-
dronic acid and aplaviroc have also been evaluated in clinic studies. TAK799 is a nonpeptide CCR5 antagonist with small molecular weight. The specific binding sites have been discovered to be related to the helices 1, 2, 3 and 7 of CCR5 to inhibit Ca\(^{2+}\) signaling.180 Zoledronic acid treatment can downregulate CCR5 expression on ViZ-T cells of cancer patients, however, the underlying mechanism is still not sure.182 Aplaviroc also specifically binds to CCR5 and prevents it from other ligands. However, trials were terminated or stagnated because of inevitably serious side effects or unsolvable difficulties.183 Although these therapies have advantages in specific target inhibition, there are still limitations. Targeted drug cannot completely block the CCR5 and tumor cells can escape from it by increasing drug resistance. Side effects also cannot be ignored.184 Clinical trials of anti-CCR5 therapies are summarized in Table 1.

Gene editing

As mentioned before, CCR5Δ32 population is exempt from the infection of HIV. In the famous case — "Berlin patient", a patient with AIDS-related acute myeloid leukemia (AML) was transplanted with CCR5Δ32 stem cells. Encouragingly, the HIV infection was successfully cured.184 This phenomenon has elicited the idea that the transplantation of CCR5Δ32 stem cells or positional locus knockout could potentially cure CCL5/CCR5-related diseases. At present, there are lots of techniques that can be implemented into the therapies against such diseases, like zinc finger nuclease (ZFN), TALEN,185 ribozyme,186 shRNA187 and CRISPR/Cas9.188

ZFN, TALEN and CRISPR/Cas9 all take use of the combination of an endonuclease and a specific CCR5 sequence recognition region. In details, ZFN has already been applied on HIV-infected patients. University of Pennsylvania has conducted a clinical trial in 2018. The CCR5 gene of CD4\(^+\) T cells from HIV positive patients was edited by ZFN (SB-728mR) (NCT02388594). Among several CCR5-TALEN designs, CCR5-TALEN-515 has been proved to be better than CCR5-ZFN.185 CCR5 modified by CRISPR/Cas9 was successfully applied on both HIV-infected patients and an acute lymphocytic leukemia case. Results show that the patient achieved complete remission for 19 months after the transplantation of CRISPR-edited stem cells.186 Gene silencing technique ribozyme and shRNA do not reprogram the cells to produce modified CCR5. Instead, they block the expression of CCR5.

Although gene therapy has been studied several years, its applications are still limited. Because there are still plenty of unknown risks. The most realistic problem is that patients with gene-modified CCR5 would have a difficult time coping with deficiency of necessary CCL5/CCR5-
| Disease or condition                  | Intervention/treatment                                                                 | Phase | NCT number         | Allocation | Actual/estimated enrollment | Status                        | Outcomes                                      |
|---------------------------------------|----------------------------------------------------------------------------------------|-------|-------------------|------------|----------------------------|-------------------------------|-----------------------------------------------|
| Kaposi's sarcoma                      | Maraviroc                                                                              | II    | NCT01276236       | NA         | 13 participants             | Completed                     | Primary/secondary endpoints                  |
| Hematologic malignancy                | Maraviroc                                                                              | II    | NCT01785810       | NA         | 37 participants             | Completed                     | Primary endpoint                             |
| Colorectal cancer                     | Maraviroc                                                                              | I     | NCT01736813       | NA         | 12 participants             | Completed                     | Primary/secondary endpoints                  |
| Metastatic colorectal cancer MSS      | Pembrolizumab/Maraviroc                                                               | I     | NCT03274804       | NA         | 20 participants             | Completed                     | Primary/secondary endpoints                  |
| Lymphoma                              | Lentivirus vector rHIV7-shl-TAR-CCR5RZ-transduced hematopoietic-progenitor cells/Carmustine/Cyclophosphamide/Etoposide/Autologous hematopoietic stem cell transplantation | I     | NCT00569985       | NA         | 5 participants              | Completed                     | Primary endpoint                              |
| Pancreatic ductal adenocarcinoma      | Stereotactic Body Radiation (SBRT)/Nivolumab/CCR2/CCR5 dual antagonist/GVAX             | I/II  | NCT03767582       | Randomized | 30 participants             | Recruiting                    |                                               |
| Colorectal neoplasms                  | Vicriviroc/Pembrolizumab                                                               | II    | NCT03631407       | Randomized | 40 participants             | Active, not recruiting        | Recruiting                                   |
| Triple negative breast neoplasms      | Leronlimab/AUC 5 Carboplatin                                                          | I/II  | NCT03838367       | Non-Randomized | 48 participants             | Recruiting                    |                                               |
| Blood cell neoplasm                   | Fludarabine/Cyclophosphamide/Thiotepa/Total-Body Irradiation/Umbilical Cord Blood Transplantation/Cellular Therapy | II    | NCT04083170       | Non-Randomized | 10 participants           | Recruiting                    |                                               |
| HIV infection                         |                                                                                       |       |                   |            |                            |                               |                                               |
| Myelodysplastic syndrome              |                                                                                       |       |                   |            |                            |                               |                                               |
| Non-Hodgkin lymphoma                  |                                                                                       |       |                   |            |                            |                               |                                               |
| Refractory anemia, adult              | Leronlimab                                                                             | III   | NCT04504942       | N/A        | 30 participants             | Recruiting                    |                                               |
| Rheumatoid arthritis                  | AZD5672/Etanercept/Placebo                                                            | II    | NCT00713544       | Randomized | 373 participants            | Completed                     | Primary/secondary endpoints                  |
| Graft-versus-host disease             | Maraviroc                                                                              | I/II  | NCT00948753       | Non-Randomized | 38 participants             | Completed                     | Primary/secondary endpoints                  |
| Hematopoietic stem cell transplantation|                                                                                       |       |                   |            |                            |                               |                                               |
| Hypertriglyceridemia                  | Maraviroc/placebo                                                                     | I     | NCT01133210       | Randomized | 27 participants             | Completed                     | Primary/secondary endpoints                  |
| Non-alcoholic steatohepatitis         | Cenicriviroc/Placebo                                                                  | II    | NCT02217475       | Randomized | 289 participants            | Completed                     | Primary/secondary endpoints                  |
| Liver insufficiency                   | Cenicriviroc                                                                           | I     | NCT02120547       | Non-Randomized | 31 participants             | Completed                     | Primary/secondary endpoints                  |
| Prediabetic state                     | Cenicriviroc/Placebo                                                                  | II    | NCT02330549       | Randomized | 45 participants             | Completed                     | Primary/secondary endpoints                  |
| Non-alcoholic fatty liver disease     |                                                                                       |       |                   |            |                            |                               |                                               |
| Type 2 diabetes mellitus              |                                                                                       |       |                   |            |                            |                               |                                               |

(continued on next page)
mediated immune/inflammatory responses. Although no CCR5Δ32-related disadvantages have been found in individuals carrying inherited CCR5Δ32 mutation, the current techniques are still not mature enough to knockout CCR5 gene without affecting the normal functioning of chemokine system.189,190

**Perspectives and conclusions**

CCL5/CCR5 as a well characterized pathways in inflammation and cancer, considerable efforts have been devoted developing therapeutic strategies. However, several points might be addressed in the translational research concerned with CCL5/CCR5-targeted therapy. (1) When it comes to small inhibitors, the antagonist of dual chemokine receptor CCR2/CCR5 seems more efficient than the inhibitor only targeting CCL5/CCR5 binding.191,192 The investigation of small molecules with dual-/multi-inhibiting properties of CCL5/CCR5 and its related pathways might be a direction in future study. (2) For the treatment of cancer, the combinational treatment of inhibitor and chemotherapy drug synergistically improved the prognosis. With the fast development of immunotherapy and cell therapy platforms for major disease, more possibilities might be found in the combinational treatment with the classic CCL5/CCR5 inhibitor and new techniques. (3) Gene therapy targeting CCL5/CCR5 is a promising field in future, however, which is substantially underpinned by the development of current techniques of gene interfering and gene delivery. The safety issue and efficacy of the gene delivery system (viral carriers or non-viral ones made into nano sizes) might be the main barriers in initiating a clinical trial of CCL5/CCR5-targeted gene therapy. Much remains to be done before the next generation of CCL5/CCR5-targeted gene therapy can bring significant clinical benefits to the patients. In this review, we illustrated the molecular factors and signaling pathways upstream or downstream of CCL5/CCR5 axis, and discussed how the pathogenesis of the diseases related to CCL5/CCR5 axis. Moreover, we highlighted several classic therapies in CCR5-related diseases and focused on the clinical trials. In summary, the CCL5/CCR5 axis is a potential target in the treatment of a wide range of diseases. With the improvement of fields such as immunology, pathology, gene editing etc., more precise therapeutic strategies targeting CCL5/CCR5 might be developed.

**Conflict of interests**

The authors have no conflicts to declare.

**Funding**

This work is supported by the Key R&D Project of Sichuan Province (No. 2020YFS0553), the Excellent Youth Foundation of Sichuan Scientific Committee Grant in China (No. 2019.JDJQ008) and the National Natural Science Foundation Regional Innovation and Development, China (No. U19A2003).
CCL5/CCR5 axis in human diseases and related treatments

Search strategy and selection criteria

Data for this review were identified by searches of MEDLINE, ClinicalTrials, PubMed, and references from relevant articles using the search terms “CCL5”, “CCR5”, “cancer”, “inflammation”, “infection” and “diseases”. Abstracts and reports from meetings were included only when they related directly to previously published work. Only articles published in English between 1998 and 2021 were included.

References

1. López-Cotarelo P, Gómez-Moreira C, Criado-García O, Sánchez L, Rodríguez-Fernández JL. Beyond chemoattraction: multifunctionality of chemokine receptors in leukocytes. Trends Immunol. 2017;38(12):927–941.
2. Hughes CE, Nibbs RJB. A guide to chemokines and their receptors. FEBS J. 2018;285(16):2944–2971.
3. Kranjc MK, Novak M, Pestell RG, Lah TT. Cytokine CCL5 and receptor CCR5 axis in glioblastoma multiforme. Radiol Oncol. 2019;53(4):397–406.
4. Nomiyama H, Osada N, Yoshie O. Systematic classification of vertebrate chemokines based on conserved synteny and evolutionary history. Gene Cell. 2013;18(1):1–16.
5. Aldinucci D, Borghese C, Casagrande N. The CCL5/CCR5 axis in cancer progression. Cancer. 2020;12(7):e1765.
6. Velasco-Velázquez M, Xolalpa W, Pestell RG. The potential to target CCL5/CCR5 in breast cancer. Expert Opin Ther Targets. 2014;18(11):1265–1275.
7. Marques RE, Guabiraba R, Russo RC, Teixeira MA. Targeting CCL5 in inflammation. Expert Opin Ther Targets. 2013;17(12):1439–1460.
8. Wierda RJ, Kuipers HF, van Eggermond MC, et al. Epigenetic control of CCR5 transcript levels in immune cells and modulation by small molecules inhibitors. J Cell Mol Med. 2012;16(8):1866–1877.
9. Schlecker E, Stojanovic A, Eisen C, et al. Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. J Immunol. 2012;189(12):5602–5611.
10. Weitzenfeld P, Ben-Baruch A. The chemokine system, and its CCR5 and CXCR4 receptors, as potential targets for personalized therapy in cancer. Canc Lett. 2014;352(1):36–53.
11. Martinez-Muñoz L, Barroso R, Dyrhaug SY, et al. CCR5/CXCR4/CX3CR1 oligomerization prevents HIV-1 gp120/120IIIB binding to the cell surface. Proc Natl Acad Sci U S A. 2014;111(19):E1960–E1969.
12. Hütter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med. 2009;360(7):692–698.
13. Abid S, Marcos E, Parpaleix A, et al. CCR2/CCR5-mediated macrophage-smooth muscle cell crosstalk in pulmonary hypertension. Eur Respir J. 2019;54(4):1802308.
14. Wang SW, Wu HH, Liu SC, et al. CCL5 and CCR5 interaction promotes cell motility in human osteosarcoma. PloS One. 2012;7(4):e35101.
15. Jiao X, Nawab O, Patel T, et al. Recent advances targeting CCR5 for cancer and its role in immuno-oncology. Canc Res. 2019;79(19):4801–4807.
16. Suarez-Carmona M, Chaorentong P, Kather JN, et al. CCR5 status and metastatic progression in colorectal cancer. Oncoimmunology. 2019;8(9):e1626193.
17. Huang CY, Fong YC, Lee CY, et al. CCL5 increases lung cancer migration via PI3K, Akt and NF-kappaB pathways. Biochem Pharmacol. 2009;77(5):794–803.
18. Ridley AJ, Schwartz MA, Burridge K, et al. Cell migration: integrating signals from front to back. Science. 2003;302(5651):1704–1709.
19. Jiao X, Velasco-Velázquez MA, Wang M, et al. CCR5 governs DNA damage repair and breast cancer stem cell expansion. Canc Res. 2018;78(7):1657–1671.
20. Hermida MA, Dinesh Kumar J, Leslie NR. GSK3 and its interactions with the PI3K/AKT/mTOR signalling network. Adv Biol Regul. 2017;55:15–26.
21. Deng S, Dai G, Chen S, et al. Dexamethasone induces osteoblast apoptosis through ROS-PI3K/AKT/GSK3 signalling pathway. Biomed Pharmacother. 2019;110:602–608.
22. Chen Y, Hu Y, Yang L, et al. Runx2 alleviates high glucose-suppressed osteogenic differentiation via PI3K/AKT/GSK3β/β-catenin pathway. Cell Biol Int. 2017;41(8):822–832.
23. Lin J, Song T, Li C, Mao W. GSK-3β in DNA repair, apoptosis, and resistance of chemotherapy, radiotherapy of cancer. Biochim Biophys Acta Mol Cell Res. 2020;1867(5):e118659.
24. Massmann D, Park S, Hall MN. mTOR signalling and cellular metabolism are mutual determinants in cancer. Nat Rev Canc. 2018;18(12):744–757.
25. Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR signalling in cancer. Front Oncol. 2014;4(4):64.
26. Zhang C, Yang C, Feldman MJ, et al. Vorinostat suppresses hypoxia signaling by modulating nuclear translocation of hypoxia inducible factor 1 alpha. Oncotarget. 2017;8(34):56110–56125.
27. Schödel J, Gramp S, Maher ER, et al. Hypoxia, hypoxia-inducible transcription factors, and renal cancer. Eur Urol. 2016;69(4):646–657.
28. McGettrick AF, O’Neill LAJ. The role of HIF in immunity and inflammation. Cell Metab. 2020;32(4):524–536.
29. Dolcet X, Llobet D, Pallares J, Matias-Guiu X. NF-kB in development and progression of human cancer. Virchows Arch. 2005;446(5):475–482.
30. Liu Y, Li ZH, Zhang L, Lu SB. ADAM8 promotes chondrosarcoma cell migration and invasion by activating the NF-κB/MMP-13 signaling axis. Anticancer Drugs. 2019;30(7):714–721.
31. Ha SH, Kwon KM, Park JY, et al. Esculentoside H inhibits colon cancer cell migration and growth through suppression of MMP-9 gene expression via NF-kB signaling pathway. J Cell Biochem. 2019;120(6):9810–9819.
32. Yin Y, Li F, Shi J, Li S, Cai J, Jiang Y. MIR-146a regulates inflammatory infiltration by macrophages in polymyositis/dermatomyositis by targeting TRAF6 and affecting IL-17/ICAM-1 pathway. Cell Physiol Biochem. 2016;40(3–4):486–498.
33. de Oliveira CE, Oda JM, Losi Guembarovski R, et al. CC chemokine receptor 5: the interface of host immunity and cancer. Dis Markers. 2014;2014:126954.
34. Samatar AA, Poulikakos PI. Targeting RAS-ERK signalling in cancer: promises and challenges. Nat Rev Drug Discov. 2014;13(12):928–942.
35. Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci. 2011;36(6):320–328.
36. Ishida M, Ishida T, Nakashima H, et al. Mnk1 is required for angiotensin II-induced protein synthesis in vascular smooth muscle cells. Circ Res. 2003;93(12):1218–1224.
37. Romeo Y, Zhang X, Roux PP. Regulation and function of the RSK family of protein kinases. Biochem J. 2012;441(2):553–569.
38. Slack C, Alic N, Foley A, Cabecinha M, Hoddinott MP, Partridge L. The Ras-ERK-ETS-signaling pathway is a drug target for longevity. Cell. 2015;162(1):72–83.
39. Torii S, Kusakabe M, Yamamoto T, Maekawa M, Nishida E. Sef is a spatial regulator for Ras/MAP kinase signaling. Dev Cell. 2004;7(1):33–44.
40. Wasylyk C, Criqui-Filipe P, Wasylyk B. Sumoylation of the net inhibitory domain (NID) is stimulated by PIAS1 and has a negative effect on the transcriptional activity of Net. Oncogene. 2005;24(5):820–828.

41. Aldinucci D, Casagrande N. Inhibition of the CCL5/CCR5 axis against the progression of gastric cancer. Int J Mol Sci. 2018;19(5):1477.

42. Villarino AV, Kanno Y, O’Shea JJ. Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol. 2017;18(4):374–384.

43. Regulation I, Progression C. JAK-STAT signaling: A double-edged sword of immune regulation and cancer progression. 2019;11(12):2002.

44. Zhang Q, Wang HY, Woetmann A, Raghunath PN, et al. Tumor-associated macrophages promote epigenetic silencing of genes involving DNA methyltransferase 1 in gastric cancer cells. Cancer Immunol Res. 2017;5(10):885–897.

45. Chang LY, Lin YC, Mahalingam J, et al. Tumor-derived chemokine CCL5 enhances TGF-β-mediated killing of CD8+ T cells in colon cancer by T-regulatory cells. Cancer Res. 2012;72(5):1092–1102.

46. Declerck PJ, Gilis A. Three decades of research on plasminogen activator inhibitor-1: a multifaceted serpin. Semin Thromb Hemost. 2013;39(4):356–364.

47. Mi Z, Bhattacharya SD, Kim VM, Guo H, Talbot LJ, Kuo PC. Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis. Carcinogenesis. 2011;32(4):477–487.

48. Mitra AK, Zillhardt M, Hua Y, et al. MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer. Canc Discov. 2012;2(12):1100–1108.

49. Yang T, Chen M, Yang X, et al. Down-regulation of KLF5 in cancer-associated fibroblasts inhibit gastric cancer cells progression by CCL5/CCR5 axis. Canc Biol Ther. 2018;17(10):806–815.

50. Dane K, Behrendt N, Hayer-Hansen G, et al. Plasminogen activation and cancer. Thromb Haemostasis. 2005;93(4):676–681.

51. Mgditchian T, Arakelian T, Paggetti J, et al. Targeting autophagy inhibits melanoma growth by enhancing NK cells infiltration in a CCL5-dependent manner. Proc Natl Acad Sci USA. 2017;114(44):E9271–E9279.

52. Xia L, Zhu X, Zhang L, Xu Y, Chen G, Luo J. EZH2 enhances expression of CCL5 to promote recruitment of macrophages and invasion in lung cancer. Biotechnol Appl Biochem. 2020;67(6):1011–1019.

53. Kim KH, Roberts CW. Targeting EZH2 in cancer. Nat Med. 2016;22(2):128–134.

54. Jin K, Pandey NB, Popel AS. Simultaneous blockade of IL-6 and CCL5 signaling for synergistic inhibition of triple-negative breast cancer growth and metastasis. Breast Cancer Res. 2018;20(1):54.

55. Korkaya H, Kim GI, Davis A, et al. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell. 2012;47(4):570–584.

56. Mikolajczyk TP, Nosalski R, Szczepaniak P, et al. Role of chemokine RANTES in the regulation of perivascular inflammation, T-cell accumulation, and vascular dysfunction in hypertension. Faseb J. 2016;30(5):1987–1999.

57. Lin AA, Tripathi PK, Sholl A, Jordan MB, Hildeman DA. Gamma interferon signaling in macrophage lineage cells regulates central nervous system inflammation and chemokine production. J Virol. 2009;83(17):8604–8615.

58. Knobloch M, Braun SM, Zurkirchen L, et al. Metabolic control of adult neural stem cell activity by Fasn-dependent lipogenesis. Nature. 2013;493(7431):226–230.

59. Ramirez-Martinez G, Cruz-Lagunas A, Jimenez-Alvarez L, et al. Seasonal and pandemic influenza H1N1 viruses induce differential expression of SOCS-1 and RIG-1 genes and cytokine/chemokine production in macrophages. Cytokine. 2013;62(1):151–159.

60. Shen J, Li S, Wang C, et al. Expression and biological functions of the CCL5-CCR5 axis in oral lichen planus. Exp Dermatol. 2019;28(7):816–821.

61. Murooka TT, Rahbar R, Fish EN. CCL5 promotes proliferation of MCF-7 cells through mTOR-dependent mRNA translation. Biochem Biophys Res Commun. 2009;387(2):381–386.

62. Wang Y, Du G, Shi L, Shen X, Shen Z, Liu W. Altered expression of CCN1 in oral lichen planus associated with keratinocyte activation and IL-1β, ICAM1, and CCL5 up-regulation. J Oral Pathol Med. 2020;49(9):920–925.

63. Hu JY, Zhang J, Cui JL, et al. Increasing CCL5/CCR5 on CD4+ T cells in peripheral blood of oral lichen planus. Cytokine. 2013;62(1):141–145.

64. Zhao ZZ, Sugeraman PB, Zhou XJ, Walsh LJ, Savage NW. Mast cell degranulation and the role of T cell RANTES in oral lichen planus. Oral Dis. 2001;7(4):246–251.

65. Wolf D, Ley K. Immunity and inflammation in atherosclerosis. Circ Res. 2019;124(2):315–327.

66. Zhu Y, Xian X, Wang Z, et al. Research progress on the relationship between atherosclerosis and inflammation. Bio-molecules. 2018;8(3):80.

67. Geovanini GR, Libby P. Atherosclerosis and inflammation: overview and updates. Clin Sci (Lond). 2018;132(12):1243–1252.

68. Chistiakov DA, Melnichenko AA, Grechko AV, Myasoedova VA, Orekhov AN. Potential of anti-inflammatory agents for treatment of atherosclerosis. Exp Mol Pathol. 2018;104(2):114–124.

69. Ranjit N, Diez-Roux AV, Shea S, et al. Psychosocial factors and inflammation in the multi-ethnic study of atherosclerosis. Arch Intern Med. 2007;167(2):174–181.

70. Madan M, Bishayi B, Hoge M, Amar S. Atheroprotective role of interleukin-6 in diet- and/or pathogen-associated atherosclerosis using an ApoE heterozygote murine model. Atherosclerosis. 2008;197(2):504–514.

71. Bakogiannis C, Saksche M, Stamatelopoulos K, Stellos K. Platelet-derived chemokines in inflammation and atherosclerosis. Circ Res. 2011;108(12):1108–1122.

72. Madan M, Bishayi B, Hoge M, Amar S. Atheroprotective role of interleukin-6 in diet- and/or pathogen-associated atherosclerosis using an ApoE heterozygote murine model. Atherosclerosis. 2008;197(2):504–514.

73. Bakogiannis C, Saksche M, Stamatelopoulos K, Stellos K. Platelet-derived chemokines in inflammation and atherosclerosis. Circ Res. 2011;108(12):1108–1122.

74. Li Y, Liu X, Duan W, et al. Batf3-dependent CD8α + dendritic cells aggravates atherosclerosis via Th1 cell induction and enhanced CCL5 expression in plaque macrophages. EBioMe-dicine. 2017;18:186–198.

75. Vangelista L, Vento S. The expanding therapeutic perspective of CCR5 blockade. Front Immunol. 2018;8:1981.

76. Schon A. Chemokines in vascular dysfunction and remodeling. Arterioscler Thromb Vasc Biol. 2008;28(11):1950–1959.

77. van der Vorst EP, Vanags LZ, Dunn LL, Prosser HC, Rye KA, Bursill CA. High-density lipoproteins suppress chemokine expression and proliferation in human vascular smooth muscle cells. Faseb J. 2013;27(4):1413–1425.

78. Jones KL, Maguire JJ, Davenport AP. Chemokine receptor CCR5: from AIDS to atherosclerosis. Br J Pharmacol. 2011;162(7):1453–1469.

79. Mencarelli A, Cipriani S, Francisci D, et al. Highly specific blockade of CCR5 inhibits leukocyte trafficking and reduces monocyte inflammation in murine colitis. Sci Rep. 2016;6:30802.

80. Wen Y, Lambrecht J, Ju C, Tacke F. Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities. Cell Mol Immunol. 2021;18(1):45–56.
80. Guillot A, Tacke F. Liver macrophages: old dogs and new insights. Hepatol Commun. 2019;3(6):730–743.

81. Xiong Y, Torsoni AS, Wu F, et al. Hepatic NF-kB-inducing kinase (NIK) suppresses mouse liver regeneration in acute and chronic liver diseases. Elife. 2018;7:e34152.

82. Seki E, De Minicis S, Gwak GY, et al. CCR1 and CCR5 promote hepatic fibrosis in mice. J Clin Invest. 2009;119(7):1858–1870.

83. Luedde T, Schwabe RF. NF-κB in the liver—linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2011;8(2):108–118.

84. Li M, Sun X, Zhao J, et al. CCL5 deficiency promotes liver repair by improving inflammation resolution and liver regeneration through M2 macrophage polarization. Cell Mol Immunol. 2020;17(7):753–764.

85. Patterson BK, Seetthamraju H, Dhody K, et al. Disruption of the CCL5/RANTES-CCR5 pathway restores immune homeostasis and reduces plasma viral load in critical COVID-19. medRxiv. 2020.

86. Agresti N, Lalezari JP, Amodeo PP, et al. Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: case series of four critically ill patients treated with lenitlimab. Transfus Immunohaematol. 2021;4:100083.

87. Law HK, Cheung CY, Ng HY, et al. Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells. Blood. 2005;106(7):2366–2374.

88. Alonzo 3rd F, Kozhaya L, Rawlings SA, et al. CCR5 is a receptor for Staphylococcus aureus leukotoxin ED. Nature. 2013;493(7430):51–55.

89. Glass WG, Lim JK, Cholera R, Pletnev AG, Gao JL, Murphy PM. CCR5 deficiency enhances liver macrophage generation through M2 macrophage polarization. J Immunol. 2020;12(6):1026–1037.

90. Wang X, Lee SO, Xia S, et al. Endothelial cells enhance prostate cancer metastasis via IL-6→androgen receptor → TGF-β→MMP-9 signals. Mol Canc Therapeut. 2013;12(6):1026–1037.

91. Tang CH, Yamamoto A, Lin YT, Fong YC, Tan TW. Involvement of matrix metalloproteinase-9 in CCL5/CCR5 pathway of prostate cancer metastasis via IL-6→androgen receptor → TGF-β→MMP-9 signals. Cancer Res. 2003;63(16):3514–3525.

92. Ngnangpanit K, Chaochird P, Siengdee P, et al. In vitro suppression of the MMP-3 gene in normal and cytokine-treated human chondrosarcoma using small interfering RNA. J Orthop Surg Res. 2009;4:45.

93. Brill A, Hershkoviz R, Vaday GG, Chowers Y, Lider O. Augmentation of RANTES-induced extracellular signal-regulated kinase mediated signaling and T cell adhesion by elastase-treated fibronectin. J Immunol. 2001;166(12):7121–7127.

94. Borghaei RC, Gorski G, Javadi M, Chambers M, NF-kappB and ZBP-89 regulate MMP-3 expression via a polyspecific site in the promoter. Biochem Biophys Res Commun. 2009;382(2):269–273.

95. Borghaei RC, Rawlings Jr PL, Javadi M, Woloshin J. NF-kappB binds to a polyspecific repressor element in the MMP-3 promoter. Biochem Biophys Res Commun. 2004;316(1):182–188.

96. Kelleher FC, O’Sullivan H. Monocytes, macrophages, and osteoclasts in osteosarcoma. J Adolesc Young Adult Oncol. 2017;6(3):396–405.

97. Wang SW, Liu SC, Sun HL, et al. CCL5/CCR5 axis induces vascular endothelial growth factor-mediated tumor angiogenesis in human osteosarcoma microenvironment. Carcinogenesis. 2015;36(1):104–114.

98. Zhang Z, Dong J, Lobe CG, Gong P, Liu J, Liao L. CCR5 facilitates endothelial progenitor cell recruitment and promotes the stabilization of atherosclerotic plaques in ApoE−/− mice. Stem Cell Res Ther. 2015;6(1):36.

99. Chen Z, Yang X, Bi G, et al. Ligand-receptor interaction atlas within and between tumor cells and T cells in lung adenocarcinoma. Int J Biol Sci. 2020;16(12):2205–2219.

100. Shanbhag S, Ambinder RF. Hodgkin lymphoma: a review and update on recent progress. CA Cancer J Clin. 2018;68(2):116–132.

101. Aldinucci D, Lorenzon D, Cattaruzza L, et al. Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions. Int J Canc. 2008;122(4):769–776.

102. Casagrande N, Borghese C, Visser L, Mongiat M, Colombatti A, Aldinucci D. CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth. Haematologica. 2019;104(3):564–575.

103. Alonso SR, Tracey L, Ortiz P, et al. A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. Canc Res. 2007;67(7):3450–3460.

104. Fang R, Zhang G, Guo Q, et al. Nodal promotes aggressive phenotype via Snail-mediated epithelial-mesenchymal transition in murine melanoma. Canc Lett. 2013;333(1):66–75.

105. Liu J, Wang C, Ma X, et al. High expression of CCR5 in melanoma enhances epithelial-mesenchymal transition and metastasis via TGFβ1. J Pathol. 2019;247(4):481–493.

106. Mellado M, de Ana AM, Moreno MC, Martínez C, Rodríguez- Frade JM. A potential immune escape mechanism by melanoma cells through the activation of chemokine-induced T cell death. Curr Biol. 2001;11(9):691–696.

107. Gao T, Shen Z, Ma C, Li Y, Kang X, Sun M. The CCL5/CCR5 chemotactic pathway promotes perineural invasion in salivary adenoid cystic carcinoma. J Oral Maxillofac Surg. 2018;76(8):1708–1718.

108. Lai CK, Rao YK, Chang KR, et al. 3,3’,4’,5’-Tetramethoxyxylchalcone inhibits human oral cancer cell proliferation and migration via p53-mediated mitochondrial-dependent apoptosis. Anticancer Res. 2014;34(4):1811–1819.

109. Chuang JY, Yang WH, Chen HT, et al. CCL5/CCR5 axis promotes the motility of human oral cancer cells. J Cell Physiol. 2009;220(2):418–426.

110. Chuang JY, Yang WH, Chen HT, et al. CCL5/CCR5 axis promotes the motility of human oral cancer cells. J Cell Physiol. 2009;220(2):418–426.

111. Wu YC, Chen YC, Chang JW, Hsieh JJ, Chu Y, Wang CH. Autoimmune-related CCL5 expression in chronic dermal ulcers. Anticancer Res. 2014;34(4):1811–1819.

112. Fattahi S, Amjadi-Moheb F, Tabaripour R, Ashrafi GH, Akhavan-Niaki H. PI3K/AKT/mTOR signaling in gastric cancer: epigenetics and beyond. J Cell Physiol. 2016;231(12):4162–4170.

113. Lin J, Chen Z, Huang Z, et al. Effect of T-cadherin on the AKT/mTOR signaling pathway, gastric cancer cell cycle, migration and invasion, and its association with patient survival rate. Exp Ther Med. 2019;17(5):3607–3613.

114. Fan G, Martinowich K, Chinn MH, et al. DNA methylation controls the timing of astrogliogenesis through regulation of JAK-STAT signaling. Development. 2005;132(15):3345–3356.

115. Zhang S, Che D, Yang F, et al. Correction: tumor-associated macrophages promote tumor metastasis via the TGF-β/SOX9 axis in non-small cell lung cancer. Oncotarget. 2020;11(52):4845–4846.

116. Kim J, Bae JS. Tumor-associated macrophages and neutrophils in tumor microenvironment. Mediat Inflamm. 2016;2016:6058147.

117. Pathria P, Louis TL, Varner JA. Targeting tumor-associated macrophages in cancer. Trends Immunol. 2019;40(4):310–327.
118. Chen Y, Song Y, Du W, Gong L, Chang H, Zou Z. Tumor-associated macrophages: an accomplice in solid tumor progression. *J Biomed Sci.* 2019;26(1):78.

119. Shevryev D, Tereshchenko V. Treg heterogeneity, function, and homeostasis. *Front Immunol.* 2020;10:3100.

120. Takeuchi Y, Nishikawa H. Roles of regulatory T cells in cancer immunity. *Int Immunol.* 2015;28(8):401–409.

121. Yurchenko E, Tritt M, Hay V, Shevach EM, Belkaid Y, Piccirillo GA. CCR5-dependent homing of naturally occurring CD4+ regulatory T cells to sites of Leishmania major infection favors pathogen persistence. *J Exp Med.* 2006;203(11):2451–2460.

122. Tan MC, Goedegebuure PS, Belt BA, et al. Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. *J Immunol.* 2009;182(3):1746–1755.

123. Gabrilovich DI. Myeloid-derived suppressor cells. *Cancer Immunol Res.* 2017;5(1):3–8.

124. Kumar V, Patel S, Tygcanov E, Gabrilovich DI. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 2016;37(3):208–220.

125. Xu L, Wang H, Gong Y, et al. Nesfatin-1 regulates the lateral hypothalamic area melanin-concentrating hormone-responsive gastric distension-sensitive neurons and gastric function via arcuate nucleus innervation. *Metabolism.* 2017;67:14–25.

126. Halama N, Zoernig I, Berthel A, et al. Tumoral immune cell infiltration and its precursors. *Clin Canc Res.* 2014;20(22):5615–5624.

127. Pervaiz A, Ansari S, Berger MR, Adwan H. CCR5 blockage by maraviroc induces cytotoxic and apoptotic effects in colorectal cancer cells. *Metabolism.* 2015;64(11):1571–1577.

128. Pervaiz A, Zepp M, Georges R, et al. Antineoplastic effects of CCL5-mediated macrophage chemotaxis. *Int Med J Exp Clin Res.* 2017;63(1):279.

129. Singh SK, Mishra MK, Eltom IA, Bae S, Lillard Jr JW, Singh R. CCR5/CCL5 axis interaction promotes migratory and invasive properties of pancreatic cancer cells. *Sci Rep.* 2018;8(1):1323.

130. Yadav GG, Peethl DM, Kadam PA, Lawrence DM. Expression of CCL5 (RANTES) and CCR5 in prostate cancer. *Prostate.* 2006;66(2):124–134.

131. Aldinucci D, Colombatti A. The inflammatory chemokine CCL5 and cancer progression. *Mediat Inflamm.* 2014;2014:292736.

132. Huang R, Guo L, Gao M, Li J, Xiang S. Research trends and regulation of CCL5 in prostate cancer. *OncoTargets Ther.* 2021;14:1417–1427.

133. Katona TM, Neubauer BL, Iversen PW, Zhang S, Baldwin LA, Cheng L. Elevated expression of angioenin in prostate cancer and its precursors. *Clin Canc Res.* 2005;11(23):8358–8363.

134. Zhao R, Bei X, Yang B, et al. Endothelial cells promote metastasis of prostate cancer by enhancing autophagy. *J Exp Clin Canc Res.* 2018;37(1):221.

135. Lagana AS, Garzon S, Götte M, et al. The pathogenesis of endometriosis: molecular and cell biology insights. *Int J Mol Sci.* 2019;20(22):5615–5630.

136. Chou SY, Ajoy R, Changou CA, Hsieh YT, Wang YK, Hoffer B. Elevated expression of angiogenin in prostate cancer tumor cell lysates (TCLs) induce discrepant pro-growth and anti-growth responses. *Cancer J Clin Oncol.* 2014;63:e34.

137. Guo P, Bi K, Lu Z, et al. CCR5/CCL5 ligand-induced myeloid-derived suppressor cells are related to the progression of endometriosis. *Reprod Biomed Online.* 2013;26(4):323–336.

138. Dong B, Ding Y, Huang Q, Guan X. Different triple-negative breast cancer tumor cell lysates (TCLs) induce discrepant anti-tumor immunity by PD1/PDL-1 interaction. *Med Sci Mon Int Med J Exp Canc Res.* 2019;25:500–515.

139. Manes S, Mira E, Colomer R, et al. CCR5 expression influences the progression of human breast cancer in a p53-dependent manner. *J Exp Med.* 2003;198(9):1381–1389.

140. Wang X, Li X, Wei X, et al. PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC. *Signal Transduct Target Ther.* 2020;5(1):38.

141. Wang X, Lang M, Zhao T, et al. Cancer-FOXP3 directly activated CCL5 (RANTES) recruits FOXP3(+ ) Treg cells in pancreatic ductal adenocarcinoma. *Oncogene.* 2017;36(23):3048–3058.

142. Makinoshima H, Dezawa M. Pancreatic cancer cells activate CCL5 expression in mesenchymal stromal cells through the insulin-like growth factor-I pathway. *FEBS Lett.* 2009;583(22):3697–3703.
159. Velasco-Velázquez M, Jiao X, De La Fuente M, et al. CCR5 antagonist blocks metastasis of basal breast cancer cells. *Canc Res*. 2012;72(15):3839–3850.

160. Kawana-Tachikawa A, Llibre JM, Bravo I, et al. Effect of maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals. *PloS One*. 2014;9(1):e87334.

161. Fleishaker DL, Garcia Meijide JA, Petrov A, et al. Maraviroc, a CCR5 antagonist blocks metastasis of basal breast cancer cells. *Canc Res*. 2012;72(15):3839–3850.

162. Halvorsen EC, Hamilton MJ, Young A, et al. Maraviroc decreases CCL5-mediated migration of CCR5(+) regulatory T cells and reduces metastatic tumor growth in the lungs. *OncoImmunology*. 2016;5(6):e1150398.

163. Tanabe Y, Sasaki S, Mukaida N, Baba T. Blockade of the chemokine receptor, CCR5, reduces the growth of orthotopically injected colon cancer cells via limiting cancer-associated fibroblast accumulation. *OncoTarget*. 2016;7(30):48335–48345.

164. Pérez-Martínez L, Pérez-Matute P, Aguilera-Lizarraga J, et al. Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD). *J Antimicrob Chemother*. 2014;69(7):1903–1910.

165. Choi SW, Hildebrandt GC, Okliewicz KM, et al. CCR1/CCR5 (RANTES) receptor-ligand interactions modulate allogeneic T-cell responses and graft-versus-host disease following stem-cell transplantation. *Blood*. 2007;110(9):3447–3455.

166. Reshef R, Luger SM, Hexner EO, et al. Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. *N Engl J Med*. 2012;367(2):135–145.

167. Braunersreuther V, Steffens S, Arnaud C, et al. A novel hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model. *Mol Ther*. 2013;21(11):2123–2130.

168. Tien PC, Schneider MF, Cole SR, et al. Antiretroviral therapy increases CCL8-mediated migration of CCR5(+) regulatory T cells and reduces metastatic tumor growth in the lungs. *OncoImmunology*. 2016;5(6):e1150398.

169. Ban Y, Mai J, Li X, et al. Targeting autocrine CCL5-CCR5 axis reprograms immunosuppressive myeloid cells and reinvigorates antitumor immunity. *Canc Res*. 2017;77(11):2857–2868.

170. D’Antoni ML, Mitchell BI, McCurdy S, et al. Cenicriviroc in treatment-naive subjects with HIV-1 infection: Final results of two randomized phase III trials. *J Infect*. 2012;65(4):326–335.

171. Landovitz RJ, Angel JB, Hoffmann C, et al. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection. *J Infect Dis*. 2008;198(8):1113–1122.

172. Li M, Lu C, Zhu H, et al. Cenicriviroc ameliorates the severity of graft-versus-host disease through inhibition of CCR5 in a rat model of liver transplantation. *Am J Transl Res*. 2019;11(6):3438–3449.

173. Lefebvre E, Moyle G, Reshef R, et al. Antifibrotic effects of the dual CCR2/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis. *Plos One*. 2016;11(6):e0158156.

174. Ratziu V, Sanyal A, Harrison SA, et al. Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: final analysis of the phase 2b CENTAUR study. *Hepatology*. 2020;72(3):892–905.

175. Eksteen B, Bowlus CL, Montano-Loza AJ, et al. Efficacy and safety of cenicriviroc in patients with primary sclerosing cholangitis: PERSEUS study. *Hepatol Commun*. 2020;5(3):478–490.

176. Zhang X, Haney KM, Richardson AC, et al. Anibamine, a natural product CCR5 antagonist, as a novel lead for the development of anti-prostate cancer agents. *Bioorg Med Chem Lett*. 2010;20(15):4627–4630.

177. Zhang Y, Arnatt CK, Zhang F, Wang J, Haney KM, Fang X. The potential role of anibamine, a natural product CCR5 antagonist, and its analogues as leads toward development of anti-cancer vascular agents. *Bioorg Med Chem Lett*. 2012;22(15):5093–5097.

178. Liou JT, Mao CC, Ching-Wah Sum D, et al. Peritoneal administration of Met-RANTES attenuates inflammatory and nociceptive responses in a murine neuropathic pain model. *J Pain*. 2013;14(1):24–35.

179. Caseiro MM, Nelson M, Diaz RS, et al. Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: Final results of two randomized phase III trials. *J Infect*. 2012;65(4):326–335.

180. Qi B, Fang Q, Liu S, et al. Advances of CCR5 antagonists: from small molecules to macromolecules. *Eur J Med Chem*. 2020;208:112819.

181. Fowler DW, Copier J, Dalgleish AG, Bodman-Smith MD. Zoledronic acid causes γδT cells to target monocytes and down-regulate inflammatory homing. *Immunology*. 2014;143(4):539–549.

182. Caseiro MM, Nelson M, Diaz RS, et al. Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: final results of two randomized phase III trials. *J Infect*. 2012;65(4):326–335.

183. Shimizu S, Hong P, Arumugam B, et al. A highly efficient short hairpin RNA inhibits CCR5(+) regulatory T cells in humanized NOD.scid mice. *J Infect Dis*. 2013;207(10):1544–1549.

184. Bai J, Gorantla S, Banda N, Cagnon L, Rossi J, Akkina R. CRISPR-edited stem cells in a pancreatic islet transplantation model in vivo. *J Acquir Immune Defic Syndr*. 2019;81(4):345–353.

185. Shi B, Li J, Shi X, et al. TALEN-mediated knockout of CCR5 confers protection against infection of human immunodeficiency virus. *J Acquir Immune Defic Syndr*. 2017;74(2):229–241.

186. Bai J, Gorantla S, Banda N, Cagnon L, Rossi J, Akkina R. Characterization of anti-CCR5 ribozyme-transduced CD34+ hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo. *Mol Ther*. 2000;1(3):244–254.

187. Shimizu S, Hong P, Arumugam B, et al. A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model. *Blood*. 2010;115(8):1534–1544.

188. Xu L, Wang J, Liu Y, et al. CRISPR-edited stem cells in a patient with HIV and acute lymphocytic leukemia. *N Engl J Med*. 2019;381(13):1240–1247.

189. Telenoi A. Safety concerns about CCR5 as an antiviral target. *Curr Opin HIV AIDS*. 2009;4(2):131–135.

190. Barmania F, Pepper MS. C-C chemokine receptor type five (CCR5): an emerging target for the control of HIV infection. *Appl Transl Genom*. 2013;2:3–16.

191. Okamoto M, Toyama M, Baba M. The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro. *Antivir Res*. 2020;182:104902.

192. Miao M, De Clercq E, Li G. Clinical significance of chemokine receptor antagonists. *Expert Opin Drug Metabol Toxicol*. 2020;16(1):11–30.